PlasFree

PlasMed is an innovative Australian medical device company headed up by a dynamic team with extensive knowledge in a range of surgical specialities. Our mission is to make a real difference to people's lives through quality product developments, together with a unique service and customer orientated focus. PlasMed also understands the growing cost of healthcare in Australia, and is able to offer cost effective solutions for hospitals. The PlasMed team has been in the medical device sector for over 30 years with broad experience that spans in the fields of:. PlasMed is dedicated to providing minimally invasive solutions through utilising Radio Frequency Plasma Surgical Systems.

At Plasfer, we pioneer the next generation cell therapies for the treatment of human diseases. Plasfer, founded in 2015, is a pre-clinical stage biopharmaceutical company, located in Perugia, Umbria (Italy). Plasfer has access to a dedicated and fully equipped laboratory and administrative facilities as well as a state-of-the-art animal facility through a “spin-off” agreement with the Department of Medicine at the University of Perugia, Italy. Built on the innovative discoveries of Professor Paolo Gresele and Dr.

We are an Australian-based medical device company specialising in the development and manufacture of a patented, HVAC integrated air treatment technology for microbial elimination and treatment of all indoor environments. PlasmaShield’s proprietary bio-HEPA™ technology surpasses the inherent design weaknesses of alternative air purification and filtration technologies since it is the only scalable solution that can efficiently electrolyse aerosolised droplets and integrate into ducted HVAC systems. Our technology has a particular focus on “Performance-Based Ventilation Design”, and “Lowering HVAC capital and running costs through outside air reduction”, in compliance with code standards with no compromise on indoor air quality. To learn more about our technology and how PlasmaShield can transform your practice or office to a Virus-Free facility, simply reach out today.

HemoClear is a leading medical device manufacturing company that is dedicated to pursuing innovation in the development of practical and highly effective medical devices. Our mission is to offer new and reliable solutions for treating severe or life-threatening diseases that have limited and expensive treatment options. HemoClear improves blood transfusion treatment outcomes at lower costs and offers life-saving access to transfusion blood in major surgery, trauma, and obstetrics. HemoClear boosts autologous blood transfusion options, introducing a washing and filter procedure, that generates high-quality platelet-rich transfusion blood….. Our mission is to offer new and reliable solutions for treating severe or life-threatening diseases. At HemoClear we work with the best and brightest people in their field in a diverse and inclusive organization where everybody contributes, irrespective of cultural, ethnic, or religious background, gender, sexual orientation, health, and age. Our team consists of talented and experienced professionals, who are committed to providing the best possible care for our clients and their patients. At our company, we firmly believe that a vibrant and inclusive company culture is the foundation for success.

PuriBlood developed a unique technology for blood cell separation that is supported by a world-class research center – R&D center for membrane technology (RDCMT). PuriBlood, in conjunction with RDCMT, holds over 36+ patents supporting our core membrane technology. PuriBlood is committed to improving the blood filtration process with innovative technology of ‘Zwitterionic-bias Surface Coating Technology (ZISC technology)’. PuriBlood devotes to developing solutions for leukoreduction, cell separation, and anti-fouling materials, with a sound product development plan. To satisfy clients’ requirements for various customized products of cell separation.

Because Pluri’s placenta-derived, allogeneic product candidates do not require genetic or tissue matching prior to administration, they can potentially be delivered in almost any clinical setting. Our growing pipeline of differentiated products includes potential candidates to meet some of medicine’s most challenging unmet needs around the world.These are being developed in our in-house, Good Manufacturing Practicesmanufacturing facility. Our Chemistry, Manufacturing, and Control (CMC) was approved for use in clinical studies by key regulators, such as the U.S. The information contained in these pages is not intended to provide medical advice, recommendation or instruction on the appropriate use of Pluri’s technology, nor that Pluri technology is marketable nor fit for a particular purpose. Pluri Inc., is a public company, which securities are traded on the Tel Aviv Stock Exchange (TASE) and Nasdaq. Pluri may provide links to its filings with the SEC for informational purposes only, and not for trading or investment purposes. We may freely assign any of its rights and/or obligations herein, without limitations; provided that, your rights herein shall not be adversely affected. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.